STERIS plc

STERIS

Overview

STERIS plc provides products and services that support patient care with an emphasis on infection prevention. The company supplies consumables, services, capital equipment, and connectivity solutions for healthcare delivery and related life sciences needs. The business is organized into three reportable segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Dental was divested in fiscal 2025 and is presented as discontinued operations for comparability. Principal offices are in Dublin, Ireland (global headquarters) and Mentor, Ohio (primary administrative offices).

Segments

Healthcare

• Focus: Sterile processing departments and procedural centers (operating rooms, endoscopy suites).
• Offerings: Infection prevention consumables, capital equipment, equipment maintenance and repair, outsourced instrument reprocessing, endoscopy products and capital infrastructure.
• Customer concentration: In the year ended March 31, 2026, no single customer represented more than 10% of Healthcare segment revenues.

Applied Sterilization Technologies (AST)

• Focus: Global network of contract sterilization and laboratory testing facilities; technology-neutral across sterilization modalities.
• Offerings: Sterilization services (including ethylene oxide and other modalities), materials testing, process controls, monitoring systems, and integrated sterilization equipment support.
• Facilities: Over 60 contract sterilization and laboratory facilities worldwide.
• Customer concentration: No single customer represented more than 10% of AST segment revenues in the year ended March 31, 2026.

Life Sciences

• Focus: Support for aseptic manufacturing facilities serving biopharmaceutical and medical device manufacturers.
• Offerings: Consumables (detergents, disinfectants, sterilants), equipment maintenance, capital equipment, and services for aseptic manufacturing.
• Customer concentration: No single customer represented more than 10% of Life Sciences segment revenues in the year ended March 31, 2026.

Scale and footprint

• Locations: Approximately 250 locations worldwide (sales, administrative, manufacturing, operations) across the U.S. and more than 35 other countries; most locations are leased.
• AST footprint: More than 60 contract sterilization and laboratory facilities.
• Executive offices: Dublin (global) and Mentor, Ohio (administration).
• Examples of material owned/leased facilities:
  • Conroe, TX (owned)
  • Guadalupe, Mexico (owned)
  • Mentor, OH (owned)
  • Montgomery, AL (owned/leased)
  • Plymouth, MN (owned/leased)
  • Quebec City, Canada (owned)
  • St. Louis, MO (owned/leased)
  • Leicester, England (owned)
  • Ottawa, Canada (leased)
  • Point Richmond, CA (leased)
  • Tuusula, Finland (owned)
  • Pomezia, Italy (owned)
  • Bishop's Stortford, England (leased)
  • Franklin Park, IL (leased)
  • Sharon Hill, PA (owned)
  • Tuttlingen, Germany (leased)

Employees

• Fiscal 2026 average total employees: 17,937
  • Healthcare: 12,496
  • AST: 3,489
  • Life Sciences: 837
  • Corporate: 1,115
• Fiscal 2025 average total employees: 17,787 (Healthcare 12,341; AST 3,502; Life Sciences 834; Corporate 1,110)

Backlog (unfilled orders)

• March 31, 2026 total backlog: $490.7 million
  • Healthcare: $392.1 million
  • Life Sciences: $98.7 million
• March 31, 2025 total backlog: $452.9 million
  • Healthcare: $369.2 million
  • Life Sciences: $83.7 million
• Backlog increased in fiscal 2026 due to timing of shipments and acquisitions.

Indebtedness (as of March 31, 2026)

• Total outstanding (net of deferred financing fees): approximately $1,931.7 million
  • $1,350.0 million Senior Public Notes (issued April 1, 2021)
  • $557.8 million Private Placement Senior Notes
  • $37.8 million borrowings under Revolving Credit Facility

Intellectual property and brand

• Patents: 606 U.S. patents; 2,402 patents outside the U.S.; 94 U.S. patent applications; 235 patent applications pending elsewhere.
• Trademarks: About 2,079 registrations worldwide.
• Emphasis on quality management, regulatory compliance, and continuous improvement programs (Lean, Six Sigma-like initiatives).

Regulatory, safety, and ESG programs

• Quality and regulatory: Operates under a global Quality Management System; compliance with FDA, EPA, OSHA, NRC, and other authorities; no FDA or regulatory enforcement actions reported for fiscal 2026 in the excerpt.
• Environmental and safety: ISO 14001 and ISO 45001 accreditation at multiple facilities; OSHA VPP Star Award at 14 locations; CDP greenhouse gas reporting; ongoing environmental and energy/water efficiency initiatives.
• Corporate responsibility: Participation in industry associations (AdvaMed, MDMA, AAMI, MedTech Europe); adherence to anti-bribery and anti-corruption policies and supplier conduct codes; 3TG (conflict minerals) disclosure and responsible sourcing policies.
• Cybersecurity: Enterprise risk management–integrated cybersecurity program with an Incident Response Team; regular vulnerability testing and third-party risk management; Board and Audit Committee oversight.

Executive officers (as of March 31, 2026)

• Karen L. Burton — Senior Vice President and Chief Financial Officer (assumed Aug 2025)
• Daniel A. Carestio — President and Chief Executive Officer
• Mary Clare Fraser — Senior Vice President and Chief Human Resources Officer
• Kenneth E. Kohler — Senior Vice President and General Manager, AST
• Julia K. Madsen — Senior Vice President and General Manager, Life Sciences
• Cary L. Majors — Senior Vice President and President, Healthcare
• Lindsey M. McGowan — Chief Compliance and Quality Officer (assumed Jan 2026)
• Renato G. Tamaro — Vice President and Corporate Treasurer
• J. Adam Zangerle — Senior Vice President, General Counsel, and Company Secretary